tradmap

LTRN Earnings Lantern Pharma Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$2 -$1 $0 2022 2023 2024 2025
EPS
Net income (annual)
-$21M -$10M $0 2019 2020 2021 2022 2023 2024 2025
Net income
Return on equity (annual)
-262% -131% 0% 2019 2020 2021 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$1 -$1 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$7M -$4M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-97% 62% 220% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–17 of 17
Q2 20262026-06-30-0.882026-08-1410-Q
Q1 20262026-03-31-0.302026-05-1510-Q
FY 20252025-12-31-1.572026-03-3010-K
Q3 20252025-09-30-1.212025-11-1210-Q
Q2 20262025-06-30-0.822026-08-1410-Q
Q1 20262025-03-31-0.422026-05-1510-Q
FY 20252024-12-31-1.932026-03-3010-K
Q3 20252024-09-30-1.392025-11-1210-Q
Q2 20252024-06-30-0.972025-08-1310-Q
Q1 20252024-03-31-0.512025-05-1510-Q
FY 20242023-12-31-1.472025-03-2710-K
Q3 20242023-09-30-1.082024-11-0710-Q
Q2 20242023-06-30-0.792024-08-0810-Q
Q1 20242023-03-31-0.362024-05-0910-Q
FY 20232022-12-31-1.312024-03-1810-K
Q3 20232022-09-30-1.002023-11-0810-Q
Q2 20232022-06-30-0.792023-08-0910-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.